{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-276140","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.512663+00:00","generated_at":"2026-05-16T21:05:05.471731+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atossa advances (Z)-endoxifen regulatory path; Q3 op-ex $9.3M","bullets":["FDA Type C meeting set Nov 17 to discuss accelerated NDA path for (Z)-endoxifen in breast cancer risk reduction; written comments received.","Appointed Janet R. Rea as SVP R&D and Mark Daniel as CFO to lead commercialization readiness.","Selected PSI as CRO for planned Phase 2 mBC dose-ranging study; IND filing targeted Q4 2025, topline data in 2026.","Q3 operating expenses $9.3M (up from $6.4M); interest income $0.6M; net loss not separately disclosed.","New Israel patent issued; two US patents under post-grant challenges; majority of IP portfolio unaffected."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-276140","json":"https://secwatch.observer/filing/0001193125-25-276140.json","markdown":"https://secwatch.observer/filing/0001193125-25-276140.md","text":"https://secwatch.observer/filing/0001193125-25-276140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/0001193125-25-276140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000119312525276140/atos-20251112.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:05:05.471731+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}